Last updated on June 2020

Vidofludimus Calcium for Primary Sclerosing Cholangitis

Brief description of study

To examine the safety, tolerability, and efficacy of daily dosing with vidofludimus calcium over a 6-month period.

Detailed Study Description

Investigators will assess the following:

  1. Changes on serum alkaline phosphatase levels at 3 & 6 months.
  2. Changes in other liver biochemistries at 3 & 6 months.
  3. Changes in IL-17 &IFN levels at 6 weeks and 6 months.

Clinical Study Identifier: NCT03722576

Find a site near you

Start Over

Arizona State University

Tempe, AZ United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.